NephroGenex, Inc (NRX) Narrows Q1 Loss; Outlines FY14 Objectives

NephroGenex, Inc (NASDAQ: NRX) reported Q1 EPS of ($0.37), versus ($1.48) reported last year.

Full Year 2014 Business Objectives:

• Initiate first of two Phase 3 studies mid-2014 with Pyridorin for diabetic nephropathy;
• Complete TQT cardiac safety study in the second half of 2014;
• Complete regulatory filing with EMA for the new renal endpoint to be used in the Pyridorin Phase 3 clinical program;
• Expect to initiate pre-clinical program with intravenous Pyridorin in acute kidney injury.

For earnings history and earnings-related data on NephroGenex, Inc (NRX) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Lument Finance Trust (LFT) Misses Q2 EPS by 17c
• Assembly Biosciences (ASMB) Tops Q2 EPS by 53c